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LEVAMISOLE ADULTERATED COCAINE AND PULMONARY VASCULITIS: 
presentation of two lethal cases and brief literature review.  
 
Abstract:  
The first case reports of levamisole-related disease in cocaine users were published in 2010, 
although levamisole adulteration of cocaine was first recognized several years earlier. Currently, 
more than 70% of street cocaine seizures, in the US and the EU, contain levamisole, which could 
potentially be converted to aminorex, though the reasons for this practice still remain obscure. Here 
we report two fatal cases of isolated pulmonary vasculitis in abusers of levamisole-adulterated 
cocaine, where a complete autopsy, full toxicological analysis by gas chromatography–mass 
spectrometry (GC–MS) using a previously published method of Karch et al. and histological 
examination were performed. A control group composed of 11 cases of cocaine related deaths, 
where the presence of levamisole was excluded in blood, urine and hair, was used. Recent literature 
on the human pharmacokinetics of levamisole and aminorex is also reviewed. 
The toxicological analysis revealed positive qualitative and quantitative results for cocaine, 
benzoylecgonine and levamisole in both cases. In case 1 levamisole was found at the concentration 
of 13.5 and 61.3 mg/L in blood and urine respectively, whereas in case 2 at 17.9 and 70.2 mg/L. 
The histological examination highlighted in case 1 in heart samples microscopic evidence of the 
typical remodeling changes associated with chronic stimulant abuse, whereas lungs showed 
numerous lymphocytes surrounding and infiltrating the wall of small pulmonary vessels and a 
perivascular fibrosis with transforming fibroblasts. In case 2, the myocardial samples showed wide 
fields of myocardial necrosis characterized by hypercontraction of the myocytes with thickened Z-
lines and short sarcomeres, whereas lung samples showed a significant intimal thickening of 
arteriole walls and lymphocytic infiltration of the wall and edema. Moreover, there were also 
numerous perivascular lymphocytic infiltrates. 
Although the pathological cardiac findings have allowed us to establish the cause of death in both 
cases, the presence of pulmonary vasculitis in the lungs represent a further complication. If the 
disease had progressed to hemorrhage, it certainly would have been a contributory cause of death.  
The two cases here reported allow us to advance a hypothesis about the possible correlation 
between the consumption of levamisole adulterated cocaine and pulmonary vasculitis and the 
comparison of these findings with the control group support this hypothesis.  
However, this hypothesis is still weak, taking into consideration the fact that pulmonary vasculitis 
was detected in 2 cases only, making it impossible to exclude a different etiology of this finding.  
Only through careful histological lung examinations of further cases of fatalities, related to 
levamisole adulterated cocaine, can this hypothesis be confirmed or refuted.        






1. Introduction:  
The first case reports of levamisole-related disease in cocaine users were published in 2010 [1], 
although levamisole adulteration of cocaine was first recognized several years earlier. For many 
years levamisole was used as a safe, effective anthelmintic in humans. It is still used for that 
purpose by veterinarians and veterinary toxicologists were the first to deduce, while screening for 
race-horse doping, that levamisole was being partially converted to aminorex, therefore explaining 
why it can be found in post horserace testing [2]. Aminorex is an amphetamine-like drug with the 
proven ability to cause pulmonary hypertension in humans. Structures of levamisole and aminorex 
are given in Figure 1. 
Aminorex was once sold as an anorectic called Menocil, but only in Switzerland, Austria and 
Germany. It was withdrawn from that market in 1972, after an epidemic of deaths from idiopathic 
pulmonary hypertension (IPH), which first began in the late 1960s. In early 2000 evidence began to 
emerge that cocaine in the United States and in Europe was being adulterated with levamisole. It is 
believed that today, more than 70% of street cocaine seizures, in the US and the EU [3], contain 
levamisole, which could potentially be converted into aminorex, though the reasons for this practice 
still remain obscure.  
It has been suggested that, because aminorex is a serotonin reuptake blocker, it may act 
synergistically with cocaine to produce a greater “high.” Alternatively, aminorex has a much longer 
half-life than cocaine, and may exert an amphetamine-like effect which might prolong the 
pleasurable experience [4]. This seems a reasonable theory, although the actual conversion rate of 
levamisole to aminorex is not known. Retiform purpura, thought to be immune related, is the most 
common complication of the use of levamisole/aminorex seen today [5]. It is far more commonly 
reported than IPH, however the true incidence of pulmonary hypertension is not known, possibly 
because its presence at autopsy is much less obvious than that of retiform purpura which is so 
obvious it cannot be overlooked. Cocaine-induced pulmonary vasculitis is mentioned in an 
occasional autopsy report, but usually in association with pulmonary hemorrhage in the presence of 
other systemic diseases [6-7]. Vasculitis in cocaine users is thought to be immune related as well. 
Agranulocytosis secondary to levamisole use is occasionally reported, as are myocardial infarction 
and vascular disease [8].  
Here we report two fatal cases of isolated pulmonary vasculitis in abusers of levamisole-adulterated 
cocaine, where a complete autopsy, full toxicological analysis and histological examination were 
performed. Recent literature on the human pharmacokinetics of levamisole and aminorex is also 
reviewed. 
 
2. The cases 
2.1.  Case 1: 
A 51-year-old man with a long history of drug abuse, especially cocaine, while being taken to 
hospital because of bizarre behavior suddenly died. Although there was a minor scuffle with police, 
positional asphyxia was never an issue, and neither were Taser™ applications nor back 
compression. 
A complete autopsy was performed three days after death. The presence of a severe pulmonary 
edema (right lung 920 g, left 650 g) was notable.  Examination of the heart disclosed it was 
enlarged by almost two standard deviations above predicted size (420 grams versus 312 grams 
predicted). All the other organs were unremarkable.  
 
2.2.  Case 2: 
A 35 year-old male collapsed during a party about 30 minutes after having snorted cocaine as 
witnessed by his friends. Despite the prompt resuscitation attempts he was pronounced dead 1 hour 
later.  
According to his relatives and friends the deceased had a long history of cocaine abuse. 
A complete autopsy was performed two days later. The heart was of normal shape and size (12 cm 
x 11.5 cm x 3.5 cm) and it weighed 375 g. At the section, the left ventricular wall was moderately 
increased (15mm). All the other organs were unremarkable, only a severe pulmonary and brain 
edema was found. 
3. Materials and methods 
3.1 Toxicology 
3.1.1 Samples 
For case 1 blood and urine samples were collected, whereas for case 2 in addition to blood and 
urine samples also a hair specimen (3 cm, from the posterior vertex region of head, close to the 
scalp as recommended by the Society of Hair Testing guidelines [9]) was taken. 
 
3.1.2 Chemicals and instrumentation 
Dichloromethane (DCM), ammonium hydroxide and toluene were purchased from Panreac 
Quimica S.L.U. (Castellar del Valle` s, Spain). Sodium hydroxide (NaOH), methanol (MeOH) and 
isopropanol were acquired from Carlo Erba Reagenti (Milano, Italy). Cocaine, benzoylecgonine, 
levamisole, mephentermine (N,2-dimethyl-1-phenylpropan-2-amine), cocaine -d3 and 
benzoylecgonine-d3 were supplied from Chemical Research 2000 (Rome, Italy). Hydrochloric acid 
(HCl), disodium hydrogen phosphate and sodium dihydrogen phosphate were acquired from J.T. 
Baker (Deventen, Holland). N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) and Water 
(H2O)  were obtained from Sigma (St. Louis, MO, USA) and B. Braun (Milano, Italy), respectively.  
Analysis was carried out on a gas chromatography instrument Agilent 7890A GC coupled with an 
Agilent MSD 5975C. The column was an Agilent HP-5MS (30 m length, 0.25 mm i.d. and 0.25 
mm film thickness, Agilent Technologies). The start oven temperature was 100 °C for 2.25 min, 
and programmed to 180 °C at 40 °C /min, and 300 °C at 10 °C /min for 10 min. Electron ionization 
and selected ion monitoring (SIM) acquisition mode were used. The ions of interest were as 
follows:  m/z 182, 82, 303 for cocaine, m/z 240, 82, 361 for benzoylecgonine and m/z 73, 148, 204 
for levamisole. The underlined ions were used for quantitative analysis. 
 
3.1.3 Toxicological analysis 
All samples were analyzed by gas chromatography–mass spectrometry (GC–MS) using a 
previously published method of Karch et al. [10]. The method was readapted to the conditions of 
the present study and fully validated according to the guidelines provided by Peters et al. [11]. 
 
3.1.4 Hair analysis 
Six segments of 0.5 cm length each were analyzed. Aliquots of 25 mg of decontaminated hair were 
incubated overnight in 1 mL of 0.1 N HCl, at 45 °C, in presence of 100 ng of mix IS solution. After 
cooling, 1.0 mL of 0.1 M phosphate buffer (pH 6–7) and few drops of 2 N NaOH were added. 
Centrifugation at 4000 rpm for 5 min was followed before a solid-phase extraction (SPE) with Bond 
Elut LCR-certify 130 mg column (Agilent Technologies). Columns were pretreated with 2 mL of 
MeOH and 2 mL of 0.1 M phosphate buffer (pH 6–7); afterwards, the sample was applied and the 
washing step was carried out with 2 mL of H2O, 3 mL of 0.1 M HCl and 5 mL of MeOH. 
One mL of a mixture of DCM/isopropanol (8:2) at 2% of ammonium hydroxide was added twice as 
elution agent. The organic solution was dried under a gentle N2 stream and derivatization with 25 
mL of MSTFA at 75 °C for 15 min was followed. The residue was reconstituted with 25 mL of 
toluene and injected in the GC–MS system. 
 
3.1.5 Biological fluids 
Urine (1 mL) and blood (1 mL) samples were diluted with 2 mL of H2O and 1000 ng of IS mix 
solution was added. Afterwards, 2.0 mL of 0.1 M phosphate buffer (pH 6–7) and a few drops of 2 N 
NaOH were added. The same SPE and derivatization procedures as above described for hair 
analysis were then performed. 
 
3.2 Histological examination 
For histological analysis the following samples were collected in case 1 and case 2 and fixed in 
10% neutral buffered formalin: brain, lung, heart, liver, kidney, spleen, adrenal glands, thyroid, 
pancreas and cutis. All samples after fixation were paraffin-embedded, sectioned at 6 μm thickness 
and stained with haematoxylin and eosin. 
3.3 Control group 
Cases of cocaine related deaths, where the presence of levamisole was excluded in blood, urine and 
hair, were retrospectively reviewed from our archive. For all selected cases a complete autopsy, 
toxicological and histological analyses were performed. All cases of polydrug abuse have been 




4.1 Toxicological findings 
Positive qualitative and quantitative results were obtained for cocaine, benzoylecgonine and 
levamisole in both cases. The results are given in Table I. Hair toxicological findings for case 2 are 
shown in Figure 2. Extracted ion chromatogram of levamisole obtained from the urine sample of 
case 2 and levamisole mass spectra are given in Figure 3A and B.  
  
4.2 Histological results  
Case 1 
The heart samples showed microscopic evidence of the typical remodeling changes associated with 
chronic stimulant abuse (Fig. 4A and B). As would be expected in a chronic cocaine abuser, there 
was wide spread interstitial fibrosis and evidence of extensive myocardial remodeling. The presence 
of severe pulmonary edema and lymphocytes surrounding and infiltrating the wall of small 
pulmonary vessels was notable. Moreover, a perivascular fibrosis with transforming fibroblasts was 
found (Fig. 5A and B). There were no hemorrhages, and no micro-thrombi.   
 
Case 2  
The myocardial samples showed wide fields of myocardial necrosis characterized by 
hypercontraction of the myocytes with thickened Z-lines and short sarcomeres. 
Lung samples showed a significant intimal thickening of arteriole walls and lymphocytic infiltration 
of the wall and edema. Moreover, there were also numerous perivascular lymphocytic infiltrates 
(Fig. 5C and D).  
Histological examinations of the other organs did not reveal any pathology, except for wide spread 
visceral congestion. 
 
In both cases the vascular infiltrate found in lung samples stained with haematoxylin and eosin was 
characterized by immuhistochemistry and a mixed mature B (CD20+) and T (CD3+) lymphocytic 
infiltrate was highlighted.  
 
4.3 Control group 
  
Eleven cases were identified; all data regarding age, sex, toxicological and pulmonary histological 
findings and the cause of death are reported in Table II. The main pulmonary findings at histology 
were: from a severe to a moderate pulmonary edema (6 cases, 54.5%), the presence of hemosiderin 
laden macrophages (3 cases, 27.3%), etc. The cause of death was cardiac in 8 cases (72.7%), 
excited delirium in 2 cases (18.2%) and pulmonary in 1 case (9.1%).     
 
5. Discussion 
The population pharmacokinetics of levamisole and aminorex have been characterized. Levamisole 
can be detected for up to 36 hours after ingestion in serum, but concentrations of aminorex in serum 
never exceeded the LOQ (0.34 ng/mL). Using a one compartment model, and a 100 mg oral dose of 
levamisole, Hess and his group calculated that ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 
0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h. Levamisole could 
be quantified in 42.5% of cocaine; concentrations in the positive plasma samples ranged from 2.2 to 
224 ng/mL [12].  
The pharmacokinetics of Minocel were never evaluated before it went on the market, as the 
available technology simply did not allow measurement of aminorex concentrations. Thus, several 
important questions still remain unanswered: (a) the rate of conversion of levamisole to aminorex, 
or (b) the amount of aminorex and duration of exposure to levamisole required to cause IPH. Most 
cases that occurred during the IPH epidemic began from six to nine months after aminorex use, with 
average dose ranges of 10 to 40 mg per day [13]. Currently, there is no way of knowing whether 
another epidemic of IPH may be in the making. We do know, however, that a substantial number of 
chronic abusers consume very large amounts of cocaine on a daily basis (multiple grams per day) 
[14], so the possibility of another outbreak of IPH among cocaine abusers remains a real possibility, 
especially as the formation of aminorex from levamisole seems to depend on the concentration of 
the latter. 
 
In case 1, a cardiomegally was highlighted at autopsy with obvious evidence of myocardial 
remodeling which has already been linked to chronic stimulant abuse [15]. Whether the presence of 
levamisole made the remodeling changes worse is impossible to say given the evidence at hand. 
Although pathological changes in the heart may support the cause of death, the incidental finding of 
pulmonary lymphocytic vasculitis may represent an unrecognized complication of levamisole use. 
In case 2, the findings of the segmental (6*0.5cm) analysis of the 3 cm hair sample confirm that the 
35 year-old male had a cocaine abuse history since cocaine was detected in all 6 segments. It is 
accepted that head hair grows at an average rate of 1 cm each month [16-18], so the results here are 
consistent with retrospective analysis of 3-months cocaine/levamisole exposure. In segments 1, 2, 4 
and 6 levamisole was detected suggesting that the administered cocaine was adulterated with the 
last drug intake. The first hair segment, the one closest to the scalp, showed the highest 
concentration of levamisole, which suggested consumption of adulterated cocaine during 
approximately the last 15 days of the deceased life. As in the first case, the pathological cardiac 
findings allowed us to establish the cause of death.   
Taking into account the presence of pulmonary lymphocytic vasculitis in both cases and the 
possible correlation of this finding with levamisole it is interesting to note that in none of the cases 
of the control group pulmonary vasculitis was detected. The most common finding in lung samples 
of this group was a pulmonary edema (54.5% of cases), which was not found in the two cases here 
reported.  
Pulmonary edema in cocaine users can represent another manifestation of catecholamine toxicity of 
the lungs, the heart, or both. Cocaine and the catecholamine excess occurring as a consequence of 
the use of cocaine, decrease myocardial contractility, lowering cardiac output, causing heart failure 
and the developing of pulmonary edema.  
Moreover, the segmental analysis of hair in the control group has allowed us to exclude a previous 
intake of levamisole, variable time ranging from approximately a month and a half (case 4) to 
approximately 5 months (case 11).  
A review of literature published in 2012 by Larocque and Hoffman [19] reported levamisole-
induced complications in cocaine users and a total of 203 cases were identified; however, only in 57 
cases the presence of levamisole was confirmed. The most common complications reported were 
neutropenia and moderate/severe cutaneous complications, especially retiform purpura with 
different degrees of necrosis and a predominant involvement of the ear lobes. Regarding pulmonary 
complications in a case series [20] 3 cases of pulmonary hemorrhage were reported.  
However, it is important to underline that all these complications have been highlighted in living 
subjects; Larocque and Hoffman [19] until December 2011 have found only three deaths as a result 
of complications secondary to levamisole-tainted cocaine and the review of the literature of the last 
three years has detected only further 2 cases of complications leading to death, possibly related to 
levamisole or its metabolite: a case of acute coronary syndrome involving a 25-year-old man with a 
history of cocaine abuse [21] and a case of pulmonary hypertension involving a 51-year-old male 
native of Tunisia [10].         
Hence, taking into consideration that the majority of data comes from living subjects and currently 
there are only a few cases of fatalities related to complications due to levamisole adulterated 
cocaine, possible complications such as pulmonary vasculitis may go unrecognized in comparison 
to cutaneous manifestations or agranulocytosis, the effects of which are more evident.     
Therefore, the two cases here described confirm the necessity of the toxicological analysis of 
levamisole and adulterants, which could represent an additional health threat [22-23] and only 
through a careful analysis of further cases can this and other complications be highlighted. Presently, 
although cocaine can be adulterated with many substances like lidocaine, dextromethorphan, 
caffeine, sugars, creatine, benzocaine etc., levamisole represents one of the most popular cocaine 
adulterants, reaching more than 80% of illicit cocaine seized within United States borders [24].  
 
 
6. Conclusions  
Although the pathological cardiac findings have allowed us to establish the cause of death in both 
cases, the presence of pulmonary vasculitis in the lungs represent a further complication. If the 
disease had progressed to hemorrhage, it certainly would have been a contributory cause of death.  
The two cases here reported allow us to advance a hypothesis about the possible correlation 
between the consumption of levamisole adulterated cocaine and pulmonary vasculitis and the 
comparison of these findings with the control group support this hypothesis. Moreover, in one of 
the two cases (case 2) it was possible to document a cocaine abuse history with levamisole 
adultered cocaine during the 3 months previous to death.   
However, this hypothesis is still weak, taking into consideration the fact that pulmonary vasculitis 
was detected in 2 cases only, making it impossible to exclude a different etiology of this finding.  
Only through careful histological lung examinations of further cases of fatalities, related to 
levamisole adulterated cocaine, can this hypothesis be confirmed or refuted.        
Moreover, numerous further points must be clarified; whether or not pulmonary vasculitis 
represents an acute or chronic complication of levamisole use and therefore segmental hair analysis 
is highly recommended in order to document a possible previous levamisole intake, if 
levamisole/aminorex induced-pulmonary vasculitis has been present for some time before 
converting to hemorrhagic vasculitis and finally if it represents an isolated finding or a 
manifestation of a multi-organ disease.  
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Table I: Quantitative results for cocaine, benzoylecgonine and levamisole detected in 













COC = cocaine; BZE = benzoylecgonine; LEV = levamisole. 
Case no Analytes Blood (mg/L) Urine (mg/L) 
 
Case 1 
COC 0.74 26.3 
BZE 1.8 93.6 
LEV 13.5 61.3 
 
Case 2 
COC 0.95 34.7 
BZE 4.6 248.3 
LEV 17.9 70.2 
Table II – Control group: 11 cases of cocaine related death where the presence of levamisole was 
excluded.  
Case/Age/Sex 
Toxicology (mg/L) Histological 
pulmonary 
findings 
Cause of death Blood Urine  
COC BZE COC BZE 










2/31/M 0.92 1.26 No urine Severe edema Cardiac 
3/37/F 0.62 0.95 38.9 94.1 Moderate edema Cardiac 

















6/29/M 0.57 0.85 2.13 3.19 Moderate edema Cardiac 








8/27/M 2.10 3.61 88.4 113.6 Severe edema 
Excited 
delirium 























thickness of the 
alveolar 
walls 








Fig. 2. Quantitative results for cocaine, benzoylecgonine and levamisole detected in the 


























Segments of 0.5 cm each 
Cocaine BZE Levamisole
 
Fig. 3. Extracted ion chromatogram of the levamisole positive urine sample (case 2) 
(A), levamisole mass spectra (B). 
 
	   	  
Fig. 4. (H&E) Case 1: myocardial disarray and abnormal fat deposits (A); Medial hypertrophy of 
small vessels, presence of autophagic hypertrophic myocytes and interstitial fibrosis (B).     	  
A	   B	  
  
Fig. 5. (H&E). A and B case 1: lymphocytes surrounding and infiltrating the wall of 
small pulmonary vessels and perivascular fibrosis with transforming fibroblasts. 
C and D case 2: intimal thickening of arteriole walls and lymphocytic infiltration and 
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